Race to Remission: Timely Diagnosis and Early,
Intensive Treatment in Rheumatoid Arthritis Care

Advances in knowledge about rheumatoid arthritis (RA) and its pathophysiology have contributed to the development of disease-modifying antirheumatic drugs (DMARDs) that promise markedly improved patient outcomes. The availability of a burgeoning number of DMARDs means that the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) now both advocate a "treat-to-target" (T2T) approach with the goal of achieving sustained remission or low disease activity to prevent joint damage and other consequences of RA, thereby optimizing patients' functional status and quality of life.

This series of continuing medical education (CME) activities provides guidance from an international faculty of renowned rheumatologists as well as interactive education to guide clinicians in optimal RA management. Core elements of care covered include the role of timely diagnosis and prompt initiation of appropriately selected DMARD therapy, ongoing patient monitoring to assess disease status and response to treatment as part of the T2T strategy, and shared decision-making to ensure that patients are fully engaged in their own care.  

Educational Objectives

At the conclusion of this case clinic, participants should be better able to:

  • Recognize the full spectrum of rheumatoid arthritis (RA) manifestations, including the impact on functional ability, quality of life, and elevated risk for myocardial infarction and stroke
  • Describe RA pathogenesis and the specific targets of available and emerging disease-modifying antirheumatic drugs (DMARDs)
  • Identify which patients are suitable candidates for targeted DMARDs and determine optimal timing for initiation of DMARD treatment
  • Implement guidelines-directed, treat-to-target strategies to achieve RA remission or low disease activity
  • Incorporate shared decision-making strategies in RA treatment decisions
  • Individualize RA treatment plans with consideration for patient-centric issues such as tolerability and likelihood of adherence in addition to efficacy and safety

Featured Resources For Your Patients

Hear a brief introduction from a patient on how support and education can help patients as they navigate rheumatoid arthritis, then check out (and feel free to share) the resources in the right column of this page.


Roy Fleischmann, MD, MACR - Chair
Medical Director
Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern
  Medical Center
Dallas, Texas, USA

Bernard Combe, MD, PhD
Professor of Rheumatology
Montpellier University
Head, Bone and Joint Department
Montpellier University Hospital
Montpellier, France

Provided by

These activities are supported by an
educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


The American College of Rheumatology (US)

Rheumatic disease in general:

Rheumatoid arthritis:

The Arthritis Foundation (US)

National Institutes of Health (US)
National Institute of Arthritis and Musculoskeletal and Skin Diseases

Centers for Disease Control and Prevention (US)

Creaky Joints (part of the nonprofit Global Healthy Living Foundation) (US)

European League Against Rheumatism; Standing Committee of People With Arthritis and Rheumatism (EULAR PARE)

National Rheumatoid Arthritis Foundation (UK)

National Health Service (UK)

The Arthritis Society (Canada)

Additional Resources: